Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
AssigneeBodyBio, Inc.
InventorsEdward Kane, Patricia Kane, Brett T. Hauser
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.
Claims12
A composition for treating a subject having symptoms of diseases related to imbalance of essential fatty acids comprising:
- (a) a therapeutically effective amount of a first composition comprising a balanced phosphatidylcholine (PC);
- and (b) a therapeutically effective amount of a second composition comprising one or more cannabinoids, the balanced PC composition is a water-soluble supplement extracted from soy lecithin that comprises phospholipids and essential fatty acids;
- the phospholipids comprise phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol;
- and the essential fatty acids comprise omega 6 and omega 3 fatty acids in a ratio of 4:1 respectively, and a pharmaceutically acceptable carrier or diluent, wherein said diseases comprise seizure, depression, Alzheimer's disease, and atherosclerosis.
A kit for treating or ameliorating one or more symptoms of seizures comprising:
- a) a first composition comprising a balanced phosphatidylcholine (PC) composition;
- b) a second composition comprising one or more cannabinoids;
- and
- c) instructions for the use of the first and second compositions and the constituents.
A method of achieving an enhanced therapeutic effectiveness of cannabinoids in a subject in need thereof comprising administrating one or more cannabinoids in combination with a balanced phosphatidylcholine composition, wherein the effective therapeutic concentration of the one or more cannabinoids is reduced by about 10-100 fold when administered with said balanced phosphatidylcholine as compared to a control group that had been administered said cannabinoids alone.
Dependencies are inferred from the claim text.